<a href="https://community.sciex.com/author/commmunitysuperuser/" target="_self">SCIEX Community</a>

SCIEX Community

Glycosylation Analysis Designed for the (Protein) Masses

Nov 9, 2016 | Biopharma, Blogs | 0 comments

A variety of post-translational modifications (PTMs) can impact a biotherapeutic protein’s mass, but none are as common as glycosylation.[1] Hence, the headline for a recent article in Genetic Engineering and Biotechnology News,  “Post-Translational Icing on the Biologics Cake,” featuring comments from Sean McCarthy, Ph.D., Global Market Manager of Biologics at SCIEX.

About the Article: Biotherapeutic protein glycosylation plays a key role in whether or not a biologic drug can effectively treat disease, making the detection and characterization of these glycan structures an important topic for pharmaceutical developers.  Dr. McCarthy gives his take on using different liquid chromatography separation techniques together with mass spectrometry to go after low-level immunogenic glycan epitopes on biotherapeutics, which could elicit an undesirable immune response in patients. The development of  focused instrumentation and software solutions to meet the needs of biologics characterization workflows are profiled in this article, with a focus on the SCIEX TripleTOF® 6600 MS system coupled with BioPharmaView™ software. Together, the TripleTOF system and BioPharmaView software can profile intact protein glycoforms, or comprehensively identify and quantitate specific glycopeptides.Read the Article >

Want to Know More about Glycan Analysis?

Discover innovations with this useful ‘Glycan Analysis Solution Guide’ that helps you:

  • Resolve microheterogeneity and profile glycans
  • Prep and analyze 96 glycan samples in <6 hours
  • Characterize glycosylated proteins using LC-MS technology
  • Detect low abundance glycan forms with CESI-MS
  • Access notable publications and webinars

About Dr. McCarthy:
Sean M. McCarthy received his degree in Chemistry from the University of Vermont in 2005, followed by his NIH postdoctoral associate within the Department of Pathology at the same institution. His work centered on environmental oxidative stress related diseases using a variety of biochemical and mass spectrometric techniques. Dr. McCarthy has worked in the mass spectrometry industry since 2008 and has held several scientific and business development positions to address pharmaceutical and biopharmaceutical characterization. Dr. McCarthy is currently the Global Market Manager of Biologics at SCIEX, where his focus is on delivering targeted solutions for biopharmaceutical characterization.

[1] http://www.sciencedirect.com/science/article/pii/S135964461600026X

Why SCIEX partners with experts around the world

Innovation in mass spectrometry does not happen in isolation. Some of the most impactful scientific advances emerge from highly specialized research communities – proteomics experts developing new peptide identification workflows, metabolomics researchers curating spectral databases, toxicologists building compound libraries, and biopharma scientists creating novel characterization methods.

Managing ADC characterization: The challenge of turning complexity into confidence

Unlike traditional monoclonal antibodies, ADCs combine an antibody backbone with linker chemistry and a cytotoxic payload. This multi-component architecture introduces overlapping layers of heterogeneity, including drug-to-antibody ratio (DAR) distributions, charge variants, post-translational modifications, and structural changes at both the intact and subunit levels. Across ADC development, these characteristics are considered critical quality attributes that must be characterized, understood, and monitored.

3 reasons ZT Scan DIA is changing the game in metabolomics

For years, metabolomics researchers have faced a frustrating reality: modern high-resolution mass spectrometers can detect tens of thousands of molecular features, yet only a fraction can be confidently identified. The challenge is no longer finding molecules. It is generating the high-quality MS/MS data needed to confidently assign structures and extract meaningful biological insights.

Posted by

Community Manager
Tags
Biopharmabiotherapeutic developmentblazechargecompanycoupledevelopmentjobmachinemassmoneynewnumberpowerproteinrapidsystemtechnologytimevariantwork

0 Comments

Submit a Comment

SCIEX Now™ support network
The destination for all your support needs.
Contact support

The power of precision

Visit Danaher site Danaher
© Copyright 2024 SCIEX

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures. Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks). Echo® and Echo® MS + system are trademarks or registered trademarks of Labcyte, Inc. in the United States and other countries, and are being used under license.

Pin It on Pinterest

Share This

Share this post with your network